Palatin Technologies Inc (PTN)
Palatin Technologies Inc. is a biopharmaceutical company listed on NASDAQ as common stock under the ticker PTN. The company focuses on medicines that act on the melanocortin receptor system and describes its work as developing first-in-class treatments based on molecules that modulate that pathway. Its pipeline includes PL7737, an oral small-molecule MC4R agonist in preclinical development, as well as long-acting peptide MC4R agonists. Palatin is also studying Bremelanotide in combination with Tirzepatide for obesity in a Phase 2 trial and Bremelanotide co-formulated with a PDE5 inhibitor for erectile dysfunction in patients not adequately responsive to PDE5 inhibitor monotherapy. Additional programs include PL9643 for dry eye disease and other inflammatory eye conditions, along with oral PL8177 for inflammatory bowel diseases. The company was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PTN
|
$6.85
|
-19.3% Downside
|
Overvalued
|
$53.50
|
530.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-2.6x
|
1.5x
|
1.3x
|
16.031 M
|
6.514 M
|
1.8%
|
77.7%
|
-45.7
|
—
|
239.8%
|
